Schrage, Yvonne M <br/><br/>
Kinome profiling of chondrosarcoma reveals SRC-pathway activity and dasatinib as option for treatment.  [electronic resource] 

 -  Cancer research  Aug 2009 
 - 6216-22 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1538-7445 
<br/><br/><label>Standard No.: </label>10.1158/0008-5472.CAN-08-4801  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Benzamides<br/>Cell Line, Tumor<br/>Chondrosarcoma--drug therapy<br/>Dasatinib<br/>Glycogen Synthase Kinase 3--metabolism<br/>Glycogen Synthase Kinase 3 beta<br/>Humans<br/>Imatinib Mesylate<br/>Jurkat Cells<br/>MAP Kinase Signaling System--drug effects<br/>Piperazines--pharmacology<br/>Protein Kinase Inhibitors--pharmacology<br/>Proto-Oncogene Proteins c-akt--metabolism<br/>Pyrimidines--pharmacology<br/>Thiazoles--pharmacology<br/>raf Kinases--metabolism<br/>ras Proteins--metabolism<br/>src-Family Kinases--metabolism